M. Wessels

Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.

D. Kasper, M. Wessels, L. Paoletti, 1996, The Journal of clinical investigation.

Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.

D. Kasper, M. Wessels, L. Paoletti, 1999, The Journal of infectious diseases.

Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome".

Jaideep P. Sundaram, Christopher R. Hauser, Samuel V. Angiuoli, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Characterization of the Linkage between the Type III Capsular Polysaccharide and the Bacterial Cell Wall of Group BStreptococcus *

D. Kasper, M. Wessels, T. Krick, 2000, The Journal of Biological Chemistry.

Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine

D. Kasper, M. Wessels, L. Paoletti, 1992, Infection and immunity.

Group B Streptococcus Type III Glycoconjugate Vaccines

D. Kasper, M. Wessels, L. Paoletti, 1992 .

The alpha-L-(1----2)-trirhamnopyranoside epitope on the group-specific polysaccharide of group B streptococci

A. Gamian, D. Kasper, R. Feldman, 1991, Infection and immunity.

Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae

Ian T. Paulsen, Jonathan A. Eisen, Scott Peterson, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Regulation of Virulence by a Two-Component System in Group B Streptococcus

D. Kasper, M. Wessels, Shengmei Jiang, 2005, Journal of bacteriology.